Emilie A. Wilkes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emilie A. Wilkes has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Guruprasad Padur Aithal
Department of Hepatology Nottingham University Hospitals NHS Trust Nottingham UK
3 shared publications - Aloysious D. Aravinthan
Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK
2 shared publications - Indra Neil Guha
NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom
2 shared publications - Mohsan Subhani
Nottingham Digestive Diseases Centre (NDDC), Translational Medical Sciences, School of Medicine, University of Nottingham, NG7 2UH, UK
2 shared publications - Pramudi Wijayasiri
NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, UK; Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, UK
2 shared publications - Stephen D. Ryder
Nottingham University Hospitals NHS Trust Nottingham UK
2 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by Elsevier in Clinical Medicine
- Vol. 26 (1) , 100538
Outcomes following nurse-led day-case paracentesis
- 26 November 2025
- Published by Elsevier in Clinical Medicine
- Vol. 26 (1) , 100538
Open AccessOutcomes following nurse-led day-case paracentesis
P97 Transient elastography in community alcohol services: can it be an adjunct and impact drinking behaviour?
Introduction Alcohol is the leading cause of cirrhosis in western populations. Early identification of high-risk drinkers followed by intervention is an effective way to reduce harm. We aim to assess the feasibility of integrating transient elastography (TE) into community alcohol services and to determine its impact on modifying drinking behaviours. Method A prospective cohort study was conducted at a community alcohol clinic in Nottingham (April-2012 to March-2014). Patients (>18years) with a primary alcohol problem were recruited. Those known to liver services or to have chronic liver disease were excluded. Significant liver fibrosis was defined by a liver stiffness measure (LSM) of >8 kilopascals (kPa). Follow-up was for a minimum of six months. Data were descriptively analysed for significant differences between patients with a normal LSM versus raised LSM. Results 156 patients were invited; n=87 attended and n=86 underwent successful TE. The majority were male (n=53, 70.0%) and the mean age was 46.3 years (SD +/-9.8). Median liver stiffness was 6.9kPa. Clinically significant liver fibrosis was identified in n=33 (38.4%), of which n=6 were in cirrhotic range (≥15 kPa). Baseline median self-reported alcohol intake for normal stiffness was 126 units per week and in raised stiffness was 149.0 units per week the difference was non-significant (p=0.338). Median reduction in self-report alcohol intake in whole cohort was 65.0 units per week (p=Conclusion The study demonstrated that transient elastography is a feasible tool to stratify clinically significant liver disease in community alcohol services. It can stimulate a change in high-risk drinking behaviour and a normal liver stiffness result does not provide false reassurance to participants. Comparison of cohorts
P97 Transient elastography in community alcohol services: can it be an adjunct and impact drinking behaviour?
Introduction Alcohol is the leading cause of cirrhosis in western populations. Early identification of high-risk drinkers followed by intervention is an effective way to reduce harm. We aim to assess the feasibility of integrating transient elastography (TE) into community alcohol services and to determine its impact on modifying drinking behaviours. Method A prospective cohort study was conducted at a community alcohol clinic in Nottingham (April-2012 to March-2014). Patients (>18years) with a primary alcohol problem were recruited. Those known to liver services or to have chronic liver disease were excluded. Significant liver fibrosis was defined by a liver stiffness measure (LSM) of >8 kilopascals (kPa). Follow-up was for a minimum of six months. Data were descriptively analysed for significant differences between patients with a normal LSM versus raised LSM. Results 156 patients were invited; n=87 attended and n=86 underwent successful TE. The majority were male (n=53, 70.0%) and the mean age was 46.3 years (SD +/-9.8). Median liver stiffness was 6.9kPa. Clinically significant liver fibrosis was identified in n=33 (38.4%), of which n=6 were in cirrhotic range (≥15 kPa). Baseline median self-reported alcohol intake for normal stiffness was 126 units per week and in raised stiffness was 149.0 units per week the difference was non-significant (p=0.338). Median reduction in self-report alcohol intake in whole cohort was 65.0 units per week (p=Conclusion The study demonstrated that transient elastography is a feasible tool to stratify clinically significant liver disease in community alcohol services. It can stimulate a change in high-risk drinking behaviour and a normal liver stiffness result does not provide false reassurance to participants. Comparison of cohorts
- Open Access
- 17 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 477
Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?
Introduction: Alcohol is the leading cause of cirrhosis in Western populations. The early identification of high-risk drinkers followed by intervention is an effective way to reduce harm. We aim to assess the feasibility of integrating transient elastography (TE) into community alcohol services, and to determine its impact on modifying drinking behaviours. Method: A prospective cohort study was conducted at a community alcohol clinic in Nottingham, UK (April 2012 to March 2014). Patients (>18 years) with a primary alcohol problem were recruited. Those known to liver services or those known to have chronic liver disease were excluded. Significant liver fibrosis was defined by a liver stiffness of >8 kilopascal (kPa). Follow-up was for a minimum of six months. Data were descriptively analysed for significant differences between patients with a normal liver stiffness versus raised liver stiffness. Results: 156 patients were invited; n = 87 attended and n = 86 underwent successful TE. The majority were male (n = 53, 70.0%), and the mean age was 46.3 years (SD ± 9.8). Median liver stiffness was 6.9 kPa (range 3.1–75.0kPa). Clinically significant liver fibrosis was identified in n = 33 (38.4%), of which n = 6 were in the cirrhotic range (≥15 kPa). The baseline median self-reported alcohol intake for normal stiffness was 126 units per week (range 24–378) and in raised stiffness was 149.0 units per week (range 39.0–420.0); this difference was nonsignificant (p = 0.338). The median reduction in self-reported alcohol intake in the whole cohort was 65.0 units per week (range 27.0–88.0, p < 0.001); in the normal liver stiffness group it was 25.0 units per week (range 18.0–75.0, p = 0.154), and in the raised liver stiffness group it was 78.5 units per week (range 36.0–126.0, p < 0.001). Conclusion: The study demonstrated that transient elastography is a feasible tool to stratify clinically significant liver disease in community alcohol services. It can stimulate a change in high-risk drinking behaviour and a normal liver stiffness result does not provide false reassurance to participants.
- 17 February 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 477
Open AccessTransient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?
Introduction: Alcohol is the leading cause of cirrhosis in Western populations. The early identification of high-risk drinkers followed by intervention is an effective way to reduce harm. We aim to assess the feasibility of integrating transient elastography (TE) into community alcohol services, and to determine its impact on modifying drinking behaviours. Method: A prospective cohort study was conducted at a community alcohol clinic in Nottingham, UK (April 2012 to March 2014). Patients (>18 years) with a primary alcohol problem were recruited. Those known to liver services or those known to have chronic liver disease were excluded. Significant liver fibrosis was defined by a liver stiffness of >8 kilopascal (kPa). Follow-up was for a minimum of six months. Data were descriptively analysed for significant differences between patients with a normal liver stiffness versus raised liver stiffness. Results: 156 patients were invited; n = 87 attended and n = 86 underwent successful TE. The majority were male (n = 53, 70.0%), and the mean age was 46.3 years (SD ± 9.8). Median liver stiffness was 6.9 kPa (range 3.1–75.0kPa). Clinically significant liver fibrosis was identified in n = 33 (38.4%), of which n = 6 were in the cirrhotic range (≥15 kPa). The baseline median self-reported alcohol intake for normal stiffness was 126 units per week (range 24–378) and in raised stiffness was 149.0 units per week (range 39.0–420.0); this difference was nonsignificant (p = 0.338). The median reduction in self-reported alcohol intake in the whole cohort was 65.0 units per week (range 27.0–88.0, p < 0.001); in the normal liver stiffness group it was 25.0 units per week (range 18.0–75.0, p = 0.154), and in the raised liver stiffness group it was 78.5 units per week (range 36.0–126.0, p < 0.001). Conclusion: The study demonstrated that transient elastography is a feasible tool to stratify clinically significant liver disease in community alcohol services. It can stimulate a change in high-risk drinking behaviour and a normal liver stiffness result does not provide false reassurance to participants.
- Open Access
- 1 October 2021
- Published by Elsevier in JHEP Reports
- Vol. 3 (5) , 100329
Estimating the clinical prevalence of Wilson’s disease in the UK
- 1 October 2021
- Published by Elsevier in JHEP Reports
- Vol. 3 (5) , 100329
Open AccessEstimating the clinical prevalence of Wilson’s disease in the UK